Pfizer Corporation

Pfizer Vaccines, Lcc

Rinat Neuroscience Corporation

Glaxosmithkline LLC

Xiayang Qiu

Philip R Dormitzer

Ye Che

Mark Edward Ruppen

Avvari Krishna Prasad

Xin Xu

Ping Cai

Julie Jia Li Hawkins

Kena Anne Swanson

Srinivas Kodali

Luke David Handke

Lorna Del Pilar Nunez

Kristin Rachael Tompkins

KariAnn Sweeney Efferen

Xi Song

Alexey Vyacheslavovich Gribenko

Brian Robert Champion

Brian Gregory Pierce

David Michael Wyatt

James Richard Merson

Michael Dale Eisenbraun

Jaume Pons

Pavel Strop

Yasmina Noubia Abdiche

Thomas Richard Jones

Javier Fernando Chaparro Riggers

Seungil Han

Narendra B Bam

Robert B Kirkpatrick

Leonard Gabriel Contillo, Jr

Jakir Hussain Ullah

James Downey Fraser

Hong Liang

Bruce Charles Gomes

Matthew Curtis Griffor

Yuli Wang

Xiaoyuan Sherry Chi

Yuhang Liu

Xiaojie Yao

Jennifer Anne Nicki

Xinzhen Yang

Kyle Paul Heim

Julie Jia Hawkins

Philip Ralph Dormitzer

Kariann Sweeney Efferen

Lorna Del Nunez

Jr Leonard Gabriel Contillo

Kyung O Johanson

Jacab S Bongers

Ping-Yang Yeh

The present disclosure relates to RSV F protein mutants, nucleic acids or vectors encoding a RSV F protein mutant, compositions comprising a RSV F protein mutant or nucleic acid, and uses of the RSV F protein mutants, nucleic acids or vectors, and compositions.

RSV F protein mutants

The present invention relates to polypeptides and cytomegalovirus (CMV) antigens that include at least one introduced amino acid mutation relative to the amino acid sequence of the wild-type HCMV glycoprotein B (gB). In some embodiments, the polypeptide is stabilized in a conformation alternative to the gB postfusion conformation. Also disclosed are compositions including the polypeptides and uses thereof.

Human cytomegalovirus gB polypeptide

The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.

PCSK9 vaccine

The present invention relates to the provision of immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine.

The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.

PCSK9 antagonists

Growing community of inventors

Mystic, CT, United States of America

Xiayang Qiu